NEW YORK (GenomeWeb) – NeoGenomics has partnered with contract research organization Pharmaceutical Product Development (PPD) to offer pathology and molecular testing services to pharmaceutical and biotechnology customers, the companies announced today.
Under the terms of the deal, NeoGenomics will provide lab testing services to support cancer clinical trial activities performed by PPD Laboratories — a unit of PPD — on behalf of clients in the US, Europe, and Asia. The companies will also offer PPD customers companion diagnostic development services ranging from biomarker discovery to product commercialization, assistance with patient identification for cancer clinical trial enrollment, and an integrated IT solution based on PPD's Preclarus data and analytics platform.
The collaboration will focus on centralized pathology review, specialty lab services, including flow cytometry fluorescence in situ hybridization, immunohistochemistry, cytogenetics, molecular assays, next-generation sequencing, and NeoGenomics’ multiomics multiplexing methodology called MultiOmyx.
Additional terms were not disclosed.
"Working with NeoGenomics will enable us to jointly provide a premier global oncology and specialty laboratory solution for our customers," Christopher Fikry, executive vice president of PPD Laboratories, said in a statement.